INTRODUCTION:

The uncontrolled growth of cells simply called as cancer, it is a complex disease caused due to genetic cellular abnormalities. According to the epidemiological study of cancer, it is second most found disease worldwide. In the past few years there was a progressive development in the treatment of cancer the (1). Delivery of the nucleic acid (DNA, RNA) for silencing abnormal genetic activity of the cell, it could be the best option for the treatment of cancer or to prevent the tumor development (2). Treatment of gene silencing activity by RNA interference, discovered by Fire et al in 1998 (3). Nobel Prize was given to this mechanism that is RNA interference in 2006. It is not only useful treatment of cancer, but also used in other multiple disease treatments like viral diseases (4). In bringing this therapy to market, there has been huge capital invested. Scientist, Davis et al in 2010 reported the first targeted si-RNA delivery with the help of nanoparticles in humans via systemic injection⁽¹⁾.

Because of its high specificity in treatment and minor side effects, ease of synthesis in early days the RNAi therapy is more important in silencing abnormal gene expression. Most cancers are caused by genetic mutation or by oncogenic expression, hence it may be possible to treat cancer by RNAi therapy by suppressing abnormal expression of genes. The handy arbiters of RNAi are siRNA. Double strand of siRNA containing 19-23 nucleotides of the same length, having a molecular weight about 13 to 15 Kilo-Dalton. The synthetic siRNA about 22 nucleotides in length (5-6). When a complementary strand of siRNA interacts with messenger RNA (mRNA) it creates the skeleton of RNAi(7). This RNAi mechanism1^st discovered in Canorhabidities Elegance upon entry of ds-RNA in the cell causes transient of gene expression. On further inspection causes discovery of other intermediary such as Dicer enzymes and the RNA induced silencing complex (RISC) rational for siRNA is the resistance of endogenous and heterologous gene expression, it can handle any disease associated with gene expression. If the current delivery method is enable to treat effectively with the help of nanoparticles even several therapeutics are in progress for diagnosis of various diseases limiting from viral infection to hereditary disorders and cancers (3). Near about 22 RNAi based drugs have entered into clinical trials and others are in progress (4). Si-RNA are unstable in the blood stream that causes the immunogenic effects, hence the chemical modification is necessary to get a specific site of action without harmful effects. Si-RNA are usually unstable in blood stream and may leads to immunogenic effect therefore Si-RNA need to be chemically modified to get a specific site of action without harmful effect.

GENERAL MODE OF ACTION OF si-RNA (4-5, 7):-Common mode of action is presented in Figure 1.

Fig-1:-Mode of action of siRNA

ADVANTAGES OF si-RNA THERAPY:

1. It is not involved with DNA and hence, it cannot permanently modify genomes hence siRNA treatment can easily stop and controlled at any point³.

2. It acts on the post–transcriptional phase of genome execution, hence it doesn’t interact with DNA and the teratogenicity risk in gene therapy³.

3. There is no any restriction regarding the selection of targets and appropriated decided by complimentary basement pairing³.

4. High efficacy³.

5. Highly safe method³.

CURRENT TRENDS IN si-RNA DELIVERY:

Although si-RNA therapy has powerful potential for treatment, it has challenges for developing efficient and specific delivery system for systematic administration. When the nanoparticle is administered into the blood stream it gets quickly cleared from circulation by the reticuloendothelial system (RES) (2). The success of the vector which are nontoxic for cancer therapy. In gene therapy the carriers can classified into two types:

1) Viral carrier.

2) Non-viral carrier (2).

Viral carrier is highly efficient, but are having high cost as per safety and immunity concern. To overcome this problem non-viral carriers are designed and have been widely used as an alternative. In non-viral carrier generally synthetic polymers and lipid are more used for delivery of siRNA. Polymers are very suitable for gene therapy, due to safety, easiest to produce as compared to viral carrier (2). Recent non-viral systems can be classified as

1) Organic non-viral carriers.

2) Inorganic non-viral carriers (8).

Organic non-viral carriers involvelipid complexes, polymer conjugates and charged polymers (cationic). When inorganic non-viral carriers involve magnetic nanoparticles (NPs), quantum dots (QD), carbon nanotubes (CNTs) and gold NPs (8). For in vivo systemic delivery of si-RNA must have following properties.

1) The delivery system of siRNA should be biocompatible.

2) Should be bio-degradable.

3) Most important are non-immunogenic.

For more progress in delivery of siRNA chemical modification is needed (). At various locations within siRNA duplex are chemically modified to provide nucleases counter action. One of casual approach is an alteration of phosphodiester (PO₄) group tophosphotiate (PS) (9). Half–life prolongation by introducing of an o-methyl group of (2^nd-O-ME), fluro (2^nd-f) groups or a 2-methoxy ethyl(2-O-MOE) groups⁹. NPsbasedsiRNA delivery generally having size range about 10-100 nanometers either by dispersion or by using solid nanoparticles for delivery. These NPs having a smart ability to convert low soluble, low absorbable and liable biologically alive matter into assuring dispatchable drugs (10).Hollow NPs accumulate different types of enzymes, genes, drugs and may have extended circulation periodowing to hydrophilic shell, and non-recognition by the RES (10). NPs having the ability to introduce and acquired in ‘puncture’ vasculature of tumors. This episode termed as enhanced permeability and retention (EPR)(10). Researchers who work on nanotechnology or nanoparticle development are trying to improve the properties of nanoparticles like bioavailability, bio-distribution, improve efficiency and immunogenicity ⁽11^).

CARRIERS USED TO DELIVERY OF si-RNA:

1) Liposome-based NPs:

Now a days liposomes are widely studied research carriers for drug delivery (12). Different liposomal formulations for clinical drug delivery have been proven safe by scientists and can be delivered effectively to the patients (13). For transfect the nucleic acid into cells different lipoid mixture, involving lipofectamine 2000, oligofectamine and trans LT 2020 are commonly used in laboratory (11). Cationic and anionic liposomes are two basic types of liposome deigned cationic liposomes are suitable to use due to their high transfection ability (14). In 1965liposomes wasfirst platform to be applied in medicines. As the siRNA is anionic in nature and when it collides with the cationic lipids lipoplexes are formed which is about 70 nmto facilities leakage of siRNA in side cell by production of charge - less ion group within the cationic liposomal vector and further plasma membrane which is much anionic. For effective gene silencing endosome escape mechanism is required mostlysiRNA enters into the cell via endocytosis (15).Some amine based materials are made to sponsor the endosome release via the proton sponge effect such as polyethylene amine and β-amine ester which causes the breakage of endosome to escape its siRNA to the cytoplasm (16). Now a day few lipid based delivery is starting to assayed in clinical progress pipeline. Stable nucleic acid lipid particles (SNPL) which is specialized lipid nanoparticle that is one of the greatest accomplishment in systemic siRNA delivery, which is developed by tekima pharmaceuticals, in partnership with Alnylam pharmaceuticals (17). Lipid based systems involves liposomes, emulsion, cell and lipid compositions, solid lipid nanoparticles. These improved pharmacokinetics characteristics and their relative less toxicity, immunogenicity made them special.

Kim et.al set forth liver focused on delivery framework for siRNA rather than HBV these are transported by liposomal edifices made out of apolipoprotein AI, 1, 2-dioleoyl-3-trimethyl ammonium propane (DOTAP) another cholesterol by intravenous organization.Due to apolipoprotein A-I, siRNA gives a liver targeted biodistribution.

Santel et al. outlined a vasculature endothelium-focused on conveyance framework for siRNA, utilizing cationic liposomes. The segments of the liposomes included cationic β-L-arginyl-2,3-L-diaminopropio-nic corrosive N-palmityl-N-oleylamidetrihydrochloride (AtuFECT01), fusogenic 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine, and the PEGylated lipid N-(carbonylmethoxypolyethyleneglycol-2000)- 1,2-distearoyl-sn-glycero-3-phosphoethanol-amine sodium salt (DSPE-PEG). At the point when siRNA atoms focusing on qualities, for example, CD31 and Tie2, which are particularly communicated in the endothelium, were buildings to the liposomes and regulated to mouse-tail vein, the siRNAs disseminated primarily to the vascular endothelium of different organs. Decrease of target protein levels was seen in vascular endothelium of the heart, liver, and lung (9).

Peer et al. formulated systemic leukocyte-coordinated siRNA conveyance frameworks. In their study liposomes were covalently altered with hyaluronan, and hyaluronan on the liposomal surface was manipulated with hostile to integrin monoclonal counter acting agent. The lipid NPs were lyophilized and enclosed with siRNA by rehydration with water constituting protamine condensed siRNA.

Huang et al. built up a ligand-focused on and stericallystabilizedNPs formulationfor deliverance of siRNA. SiRNA was blended with a transporter DNA and edifices with protamine, an exceptionally emphatically charged peptide. The siRNA/protamine complex was covered with cationic liposomes comprising of DOTAP and cholesterol to create liposome-polycation-DNA (LPD) NPs.

2) Polymer- controlled siRNA delivery:

Polymer based delivery system widely useful to plasmid DNA and nowadays for siRNA delivery. In polymer containing delivery of siRNA includes cationic moiety acts as a core component. Synthetic polymers includes Poly Ethylene Iminine, cyclodextrin based polycation, poly-L-lysine. Natural polymers atetocollagen, chitosan are cationic polypeptides. Another interesting polymers basedsiRNA delivery system are cyclodextrin consist of polycation and nanoparticles they own adjust with the siRNA to produce colloidal particles exactly 50 nanometer diameter. Cationic polymers are more attractive because of their best stability, simple production method and they gives flexibility for chemical modification⁽¹⁸⁾Some of the best examples of cationic polymers were proposed to deliver siRNA like chitosan, polyβ amino ester, poly (amino acid) etc¹⁸. Poly (ethylene amine) is extremely inquired non- viral carrier. Branched PEI (25 kilo Dalton) is considered as golden stand of non- viral gene shipment system as it has high transfection ability. Because of its strong positive charge, it is considered as important factor related toxicity. In this toxicity of PEI is nearly related with the structure (branched or linier) as well as it’s molecular weight. Aliabdi et.al reported the lipid substituted low molecular weight (2 kilo daltan) (18).

Ahn et.al synthesized biodegradable cationic copolymers of PEI and PEG. It was observed that with increase in hydrophilicity of PEG the toxicity of copolymer decreases, to expand the poor solubility of PEI and DNA complexes, which enters degradable bond by reaction along primary amine in PEI. Moreover the PEG atomsframes a defensivelayer thatshields the polyplex structure from unwanted contents with degradation enzymes or proteins in body environment.

3) Cyclodextrin polymers:

Cyclodextrin polymers based nanocarriers receives attention and are under clinical trials (19-20).The cyclodextrin polymer having defined geometric (~70nm) and cationic structure characteristics that is advantage of siRNA. Each cyclodextrinfragment have covalently connected PEG, which have the part to balance out the nanoparticle and dodge nonspecific collaboration with blood and extracellular segment under physiological conditions (15). Calando designed IT-101 for anticancer drug delivery (21).Cyclodextrin, the preliminary transporters for these medications are common cyclic sugar made out of 6 (α-CD), 7(β-CD) D-(+)–glucose units connected by α-1,4 linkages (20). The cyclodextrinsi RNA NPs (CALAA-01, calando pharmaceuticals) enters a stage 1b clinical trial which is first in human examination incorporate foundational siRNA organization to patients (NCT00689065). In NPs conveyance framework, the siRNA is coordinated against the M2 subunit of ribonucleotide reinstructs which is basic chemical in the multiplication of malignancy cell. From the information gathered by study demonstrated that this conveyance framework could confine in the tumor cells of melanoma patients in a dosage subordinate way and gives confirmation that RNAigene silencing instrument in people by adjusted 5' fast enhancement of cDNAends (RACE) assay (15).

4) Cationic dendrimers:

Cationic dendrimers is also one of the best option for the negatively charged plasmid DNA, siRNA and antisense oligonucleotide (22-24). It is important to protect nucleic acid from serum degradation. For insurance of nucleic corrosive it can be stacked by surface adsorption or inside exemplification and activating invulnerable reaction (15). In dendrimers, mass to charge ratio is important according to their stability of siRNA. siRNA dendrimers formulation is stabilized by adjusting sufficient electrostatic interaction hence the stable complex formulate if not siRNA release from endosome into cytosol. The toxicity and immunogenicity of dendrimers are related with the surface charge of dendrimers (23). In one examination it was watched that when dendrimers were additionally adjusted with magneto flurescentnanoworms to shape dendriworms it enhances the main capacity of siRN. When dendriworms were administered in human gliblastoma cells. This siRNAdendriworms immediately disguised into the cells and after that discharge into cytosol (25).Dendriworms when conjugated with one or more focusing ligands it may lead to targeted delivery. Ex. The 9-mer luteinizing hormones releasing hormone peptide was conjugated to Poly amido amine dendrimers (PAMAM), the dendrimers quaternalized for siRNA loading and have inert quaternalized amino group (15).

5) Carbon nanotube (CNT) based siRNA delivery:

The nanotubes contains carbon atoms as cylindrical molecules. That were added to alternative to hexagonal lattice design which is of graphite sheet. Usually the diameter of CNT is in sequence of less nanometers exactly 50,000 times tiny compare to human hair. Carbon nano tubes are categorized into two general categories (10).

1) Singular walled CNTs

2) Double walled CNTs

Unique character of CNTs is, it is having sequence wise with elevated aspects proportion (>3). The CNT as a carrier for siRNA is interesting because they have ability to collaborate with macro molecules like proteins and DNA (26). Due to nano needle structure of carbon nano tubes are advised to it can freely pass the plasma membrane and then transported straight in the cytoplasm of targeted cell. Carbon nano tubes have controlled and targeted drug delivery of siRNA it is one of the best properties of carbon nano tubes. Chemotherapeutic drugs, and imaging agents, targeted ligand and different therapeutic agents can be delivered with the carbon nano tubes because they having controlled and targeted drug delivery. Theories on SWCNT is presented in Table 1:

Table 1: Theories of SWCNTs

Name of scientists	Theory
Zhang et. al	ProposedSWCNT having attached associated with –CONH-(CH2)6-NH3+CS-which capable for deliver CNTs besides to silencing the purposed gene which inhibit cancer improvement (27).
Liu et. al	Uses CNT associated with amine terminated (PEG; phospholipids (PL)-PEG2000) because of siRNA entry in human T cells and see CXCR4 receptor in 60-90% blow up (28).
Wang et. al	Proposed that ammonium associated CNTs could electrostatically stick with siRNA opposite to cyclin A2, including extension, obstacles and programmed death cells of human erythro leukemia cell line in the invitro study.

Carbon nano tubes PEI and carbon nano tube pyridinium are two carbon nano tubes are analyzed for siRNA delivery which studied in recent years these two catatonically functionalized carbon nano tubes.

Challenges in si-RNA delivery:

Si-RNA therapeutics assign the conception of ‘losing- of –work approach’ to diagnose cancer which includes avoid target proteins execution inside the cells, thus, change in the reproduction of cancer cells. Also, siRNA is not administered in DNA due to genome is not going to change permanently this gives permission to stop and control the si RNA treatment at any point of time. This fulfills the factor for controlling and safety considerations (29). However the potential of siRNA therapy is limited by it’s no more effect to target system. We overlook the extracellular and intracellular challenges in delivery of siRNA at targeted site.

There are many problems to target siRNA delivery more efficiently to cancer after meet the blood circulation by shielding them from enzymatic attack and quick renal filtration, barriers by phagocytes and un-reservoir from blood to cancer cell by circular uptake and then release from the endosome into cytoplasm and finally to be release from siRNA payload to form RISC (30). The big problem and the panning to address them are discussed below.

Administration obstacles:

Oral root is not good option for administration because it is not maintaining the stability in the intestine and which do not have permission to cross intestinal epithelial to blood circulation (31). Other way of delivery is the subcutaneous injection which having benefit of avoiding first pass metabolism by the liver of the drug and aloe the circulation via capillaries. Size and lipophilicity of the gene vector is the problem taken to be considers that avoid phagocytic cell. Hence, commonly use mode of administration is then intravenous or infusion injection.

Vascular obstacles:

The crucial state for siRNA delivery in sequence for reach the target system is crossing the vascular obstacles. Hence it is advantageous character in vasculature for successful delivery of siRNA because of discontinuous sinusoidal capillaries having larger opening entry by leaking the siRNAnanocarrier into the blood circulation. The same kind of capillaries widely occur in the liver. However, size of nanocarriers is having limits and it is up to 10 nano meter. In morphology of capillaries was occurred in cancer cell shows considerable variations of the cell composition, pericytes coverage and basement membrane and this allows the permission and the accumulation of the nano carriers in tumor cells by an episode known EPR (32).

Four things are important to make the most EPR effect:

1. Tumor’s vascular permeability.

2. Intra- tumoral interstitial pressure.

3. Inside and outside blood flow to tumor.

4. Structural obstacles driven by extracellular matrix and the tumor cell (33).

For targeting non-hepatic cancer cells thing is consider to design the therapeutics because these capillaries having so small holes (60-80 nanometer) and the endothelium is protected with continuous basement lamina, which avoid the diffusion in bulk–number of nano particles. In this kind of investigation delivery is evidently affected by the pattern of the pores, extracellular matrix, continuous basement lamina, and tightness. Another one of important mechanism that eliminates siRNA therapeutics from blood circulation by glomerular filtration in kidney. The size of pore of GFR barriers is 8 nano meter. Hence, if the nanocarriers are builds such as having 20 nano meter size then there are problems found efficiently (34-35). If siRNA therapeutics is swims to the blood stream it is necessary to take carefrom the monomolecular phagocyte system (MPS) (36). In such cases, the avoidance of important factors such as formulation on size, lipophilicity, stability, surface electrostatic nature, formulation size. If the particle size is more, they are more susceptible to phagocytosis.More amount of net charge also execute a same response because they going to form accumulation because of electrostatic force. To maintain low net charge with hydrophilic and natural molecules, PEG is used to improve the consistency of the formulation within blood circulation (37). Besides this tumor vascularity can be maintained by the supply of oxygen, few metabolites are taken in consideration because of their increase in tumor vascularity can improved efficiency of siRNAdelivery (38-39).

Immune response and safety:

It is an issue to be addressed in siRNA delivery system. This delivery is required because it does not produce harm to immune system that is non-immunogenic and should not execute any side effects (40-41). They should be designed in such a way that the innate immune system should not recognize it as a foreign particle. Specially two factors such as cytokines and interferon. This problem is solved by designing the siRNA which is of 22-23 pairs in length (42). Another technique is chemical modification of siRNA 2’- O–methylation to avoid an immune response after administration.

Cellular obstacles:

Next challenge is cellular obstacles in siRNA delivery. The cellular membrane is composed of negatively charged phospholipids in bilayer containing functional proteins. In the targeted endocytosis like receptor mediated endocytosis using as float. Aptamers transferring, another dare is endosomal escape for the successful approach of the therapeutic towards the RNA- induced silencing complex (RISC) within cytoplasm (42-47).

CONCLUSION:

Currently cancer is a foremost public health problem worldwide and the comprehensive mortality from cancer is more than AIDS, malaria, and tuberculosis. siRNApossessseveral benefits like safety, efficiency, targeting potential. Despite the fact that the achievement depends on the proficient deliverance to the anticipated site for target mRNA degradation. Diversified carriers have been explored for effective delivery of siRNA. Challenges to siRNA delivery need to be addressed and based on this designing of carriers should be done to transport siRNA at specific site with less toxicity.

REFRANCES:

1. Saraswathy M, Gong S. Recent developments in the co-delivery of siRNA and small molecule anticancer drugs for cancer treatment. Materials Today. 2014 Aug 31;17(6):298-306.

2. Guo S, Huang L. Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy. Journal of Nanomaterials. 2011 Jan 1; 2011:11.

3. Xu CF, Wang J. Delivery systems for siRNA drug development in cancer therapy. asian journal of pharmaceutical sciences. 2015 Feb 28;10 (1):1-2.

4. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nature materials. 2013 Nov 1;12(11):967-77.

5. Oliveira S, Storm G, Schiffelers RM. Targeted Delivery of si RNA. BioMed Research International. 2006 Jun 25;2006.

6. Young SW, Stenzel M, Jia-Lin Y. Nanoparticle-siRNA: A potential cancer therapy?. Critical reviews in oncology/hematology. 2016 Feb 29;98:159-69.

7. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nature reviews Drug discovery. 2009 Feb 1;8 (2):129-38.

8. Lee JM, Yoon TJ, Cho YS. Recent developments in nanoparticle-based siRNA delivery for cancer therapy. BioMed research international. 2013 Jun 17;2013.

9. Oh YK, Park TG. siRNA delivery systems for cancer treatment. Advanced drug delivery reviews. 2009 Aug 10;61(10):850-62.

10. Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials. 2012 Oct 31;33(29):7138-50.

11. Jeong JH, Park TG, Kim SH. Self-assembled and nanostructured siRNA delivery systems. Pharmaceutical research. 2011 Sep 1;28(9):2072.

12. Gomes-da-Silva LC, Fonseca NA, Moura V, Pedroso de Lima MC, Simões S, Moreira JN. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Accounts of chemical research. 2012 May 8;45(7):1163-71.

13. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature reviews Drug discovery. 2005 Feb 1;4(2):145-60.

14. Uchida E, Mizuguchi H, Ishii-Watabe A, Hayakawa T. Comparison of the efficiency and safety of non-viral vector-mediated gene transfer into a wide range of human cells. Biological and Pharmaceutical Bulletin. 2002;25(7):891-7.

15. Burnett JC, Rossi JJ, Zhou J, Shum KT. Nanoparticle-Based Delivery of RNAi Therapeutics&58; Progress and Challenges. Pharmaceuticals. 2013 Jan 1;6(1):85-107.

16. Schäfer J, Höbel S, Bakowsky U, Aigner A. Liposome–polyethylenimine complexes for enhanced DNA and siRNA delivery. Biomaterials. 2010 Sep 30;31(26):6892-900.

17. Rossi JJ. RNAi therapeutics: SNALPingsiRNAs in vivo.

18. Meng Q, Yin Q, Li Y. Nanocarriers for siRNA delivery to overcome cancer multidrug resistance. Chinese Science Bulletin. 2013 Oct 30;58(33):4021-30.

19. Pun SH, Bellocq NC, Liu A, Jensen G, Machemer T, Quijano E, Schluep T, Wen S, Engler H, Heidel J, Davis ME. Cyclodextrin-modified polyethylenimine polymers for gene delivery. Bioconjugate chemistry. 2004 Jul 21;15(4):831-40.

20. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nature Reviews Drug Discovery. 2004 Dec 1;3(12):1023-35.

21. Davis ME. Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Advanced drug delivery reviews. 2009 Nov 12;61(13):1189-92.

22. Alabi C, Vegas A, Anderson D. Attacking the genome: emerging siRNA nanocarriers from concept to clinic. Current opinion in pharmacology. 2012 Aug 31;12(4):427-33.

23. Singha K, Namgung R, Kim WJ. Polymers in small-interfering RNA delivery. Nucleic acid therapeutics. 2011 Jun 1;21(3):133-47.

24. Kaneshiro TL, Lu ZR. Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials. 2009 Oct 31;30(29):5660-6.

25. Agrawal A, Min DH, Singh N, Zhu H, Birjiniuk A, Von Maltzahn G, Harris TJ, Xing D, Woolfenden SD, Sharp PA, Charest A. Functional delivery of siRNA in mice using dendriworms. Acs Nano. 2009 Aug 12;3(9):2495-504.

26. Bianco A, Kostarelos K, Partidos CD, Prato M. Biomedical applications of functionalised carbon nanotubes. Chemical Communications. 2005(5):571-7.

27. Zhang Z, Yang X, Zhang Y, Zeng B, Wang S, Zhu T, Roden RB, Chen Y, Yang R. Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clinical Cancer Research. 2006 Aug 15;12(16):4933-9.

28. Liu Z, Winters M, Holodniy M, Dai H. siRNA delivery into human T cells and primary cells with carbon‐nanotube transporters. AngewandteChemie International Edition. 2007 Mar 12;46(12):2023-7.

29. Resnier P, Montier T, Mathieu V, Benoit JP, Passirani C. A review of the current status of siRNAnanomedicines in the treatment of cancer. Biomaterials. 2013 Sep 30;34(27):6429-43.

30. Kim HJ, Kim A, Miyata K, Kataoka K. Recent progress in development of siRNA delivery vehicles for cancer therapy. Advanced drug delivery reviews. 2016 Sep 1;104:61-77.

31. Haussecker D. Current issues of RNAi therapeutics delivery and development. Journal of Controlled Release. 2014 Dec 10;195:49-54.

32. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Advanced drug delivery reviews. 2011 Mar 18;63(3):136-51.

33. Kobayashi H, Watanabe R, Choyke PL. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?.Theranostics. 2014;4(1):81.

34. Jarad G, Miner JH. Update on the glomerular filtration barrier. Current opinion in nephrology and hypertension. 2009 May;18(3):226.

35. Huang Y, Hong J, Zheng S, Ding Y, Guo S, Zhang H, Zhang X, Du Q, Liang Z. Elimination pathways of systemically delivered siRNA. Molecular Therapy. 2011 Feb 1;19(2):381-5.

36. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacological reviews. 2001 Jun 1;53(2):283-318.

37. Cho K, Wang XU, Nie S, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clinical cancer research. 2008 Mar 1;14 (5):1310-6.

38. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer research. 1989 Dec 1;49(23):6449-65.

39. Li L, Wang R, Wilcox D, Zhao X, Song J, Lin X, Kohlbrenner WM, Fesik SW, Shen Y. Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery. Gene therapy. 2012 Jul 1;19(7):775-80.

40. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L, Linsley PS. Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. Rna. 2006 Jul 1;12(7):1179-87.

41. Qiu S, Adema CM, Lane T. A computational study of off-target effects of RNA interference. Nucleic acids research. 2005 Jan 1;33(6):1834-47.

42. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, Endres S. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nature medicine. 2005 Mar 1;11(3):263-70.

43. Meade BR, Dowdy SF. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Advanced drug delivery reviews. 2007 Mar 30;59(2):134-40.

44. Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, Roesch PL, Bertin SL, Reppen TW, Chu Q, Blokhin AV, Hagstrom JE. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proceedings of the National Academy of Sciences. 2007 Aug 7;104(32):12982-7.

45. Chu TC, Twu KY, Ellington AD, Levy M. Aptamer mediated siRNA delivery. Nucleic acids research. 2006 Jan 1;34(10):e73-.

46. Konishi M, Kawamoto K, Izumikawa M, Kuriyama H, Yamashita T. Gene transfer into guinea pig cochlea using adeno‐associated virus vectors. The journal of gene medicine. 2008 Jun 1;10(6):610-8.

47. Mishra DK, Balekar N, Mishra PKNanoengineered strategies for siRNA delivery: from target assessment to cancer therapeutic efficacy, Drug DelivTransl Res. 2017 Apr;7 (2):346-358. doi: 10.1007/s13346-016-0352-5.

Received on 07.05.2018 Modified on 08.06.2018

Research J. Pharm. and Tech 2018; 11(9): 4166-4172.

DOI: 10.5958/0974-360X.2018.00765.5